March 27, 2018 / 12:12 PM / 6 months ago

BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis

March 27 (Reuters) - Redhill Biopharma Ltd:

* REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING

* REDHILL BIOPHARMA -RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III GUARD STUDY WITH BEKINDA 24 MG SUCCESSFULLY MET ITS PRIMARY ENDPOINT

* BEKINDA 24 MG WAS ALSO FOUND TO BE SAFE AND WELL TOLERATED IN TREATMENT OF ACUTE GASTROENTERITIS AND GASTRITIS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below